In a recent issue of the ARCHIVES, Geschwind et al1 reported that the 14-3-3 protein test performed in different laboratories across the United States is not a sensitive test for the diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD), in contrast with the results published by European centers. We agree with the authors and with Aksamit,2 in the accompanying editorial, that the lack of centralized laboratories and formal standardization for this test in the United States is the best but not the only explanation for this discrepancy. In our opinion, 2 points deserve further comment: the issue of handling samples and a possible bias in the population studied.
Sanchez-Valle R, Graus F, Saiz A. Discrepancies in the Clinical Utility of the 14-3-3 Protein for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease. Arch Neurol. 2004;61(4):604. doi:10.1001/archneur.61.4.604-a
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: